Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | AGXT | P21549 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17504854 | 0.93 | RAB9A (0.40) | IDO1CYP1A2CYP2A6TAAR1ACHE | |
| SCHEMBL27981063 | 0.78 | ESR1 (0.60) | CYP1A2TAAR1ACHEALDH1A1MAPT | |
| SCHEMBL9346137 | 0.78 | ALDH1A1 (0.36) | CYP1A2TDP1ALDH1A1MAPTESR1 | |
| SCHEMBL988373 | 0.77 | TP53 (0.50) | IDO1TAAR1TDP1ALDH1A1MAPT | |
| SCHEMBL28654448 | 0.76 | CYP1A2 (0.48) | IDO1CYP1A2CYP2A6TAAR1ACHE | |
| SCHEMBL16809251 | 0.75 | CYP11B1 (0.35) | ALDH1A1MAPTCYP11B1CYP11B2RAB9A | |
| SCHEMBL986310 | 0.74 | ESR1 (0.61) | IDO1CYP1A2CYP2A6TAAR1ACHE | |
| SCHEMBL16621914 | 0.73 | TAAR1 (0.48) | IDO1CYP1A2TAAR1ACHETDP1 | |
| SCHEMBL3161052 | 0.72 | IDO1 (0.46) | IDO1CYP1A2CYP2A6TAAR1ACHE | |
| SCHEMBL5484080 | 0.72 | IDO1 (0.46) | IDO1CYP1A2CYP2A6TAAR1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2275427-B1 | Ruthenium-diamine complex and methods for producing optically active compounds | TAKASAGO PERFUMERY CO LTD (JP) | 2013-09-11 | — | — | EP | disclosed |
| US-8404879-B2 | Ruthenium-diamine complex and methods for producing optically active compounds | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-03-26 | — | — | US | disclosed |
| EP-2258707-B1 | Ruthenium silyl-arene complexes, and method for production thereof | TAKASAGO PERFUMERY CO LTD (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-7880025-B2 | complexing trimethyl(4-methyl-1,4-cyclohexadienyl)silane with ruthenium chloride to produce RuCl2 [trimethyl (4-methyl-1,4-cyclohexadienyl) silane] | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-02-01 | — | — | US | disclosed |
| EP-2275427-A1 | Ruthenium-diamine complex and methods for producing optically active compounds | Takasago International Corporation (JP) | 2011-01-19 | — | — | EP | disclosed |
| US-20110009646-A1 | RUTHENIUM-DIAMINE COMPLEX AND METHODS FOR PRODUCING OPTICALLY ACTIVE COMPOUNDS | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2258707-A1 | Ruthenium silyl-arene complexes, and method for production thereof | Takasago International Corporation (JP) | 2010-12-08 | — | — | EP | disclosed |
| US-20100298588-A1 | RUTHENIUM SILYL-ARENE COMPLEX , AND METHOD FOR PRODUCTION THEREOF | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-11-25 | — | — | US | disclosed |
| US-6974856-B1 | Block copolymers having polymer segment derived from oxazoline | NANOCARRIER CO., LTD. (JP) | 2005-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298588-A1 | RUTHENIUM SILYL-ARENE COMPLEX , AND METHOD FOR PRODUCTION THEREOF | SPR, LSS, SRI | IDO1 1464/4885CYP1A2 165/4885CYP2A6 296/4885 |
| US-20110009646-A1 | RUTHENIUM-DIAMINE COMPLEX AND METHODS FOR PRODUCING OPTICALLY ACTIVE COMPOUNDS | ADH5, AOC1, ADH1A | IDO1 1752/4885CYP1A2 204/4885CYP2A6 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.